IPO Stock Of The Week: Caris Pulls Back After More Than Doubling In Just Two Months
Caris stock is pulling back after more than doubling in just two months. Wait for the IPO stock to offer a new buy point. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look
In general, many current shareholders have lived through a deep correction that started after Caris Life Sciences peaked at 42.50 on Aug. 22 last year. Thus, Caris Life Sciences is still extended. Caris Life Sciences uses artificial intell…
Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Bristol Myers Squibb (BMY) been one of those stocks this year? By taking a look at the stock's year-…
Caris Life Sciences Stock Jumped 10% Yesterday. Here’s Where Shares Could Go Further in 2026.
Caris Life Sciences Stock Jumped 10% Yesterday. Here's Where Shares Could Go Further in 2026. ©TIKR Key Takeaways Sector Rally: Caris Life Sciences (CAI) stock jumped 9.61% to close at $31 on Thursday, September 17, riding a Fed-driven mar…
Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?
Revvity (RVTY) shares ended the last trading session 9.1% higher at $140.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 10.6% gain over the…
Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?
Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presenta…
Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference
Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lu…
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
Seven studies will be presented, including two mini oral presentations and a poster tour presentation IRVING, Texas, Sept. 2, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading TechBio company, today announced that research…
These ten healthcare stocks posted the biggest gains over the past month
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images As the month of August 2026 comes to a close, the broader stock market has exhibited a mix of late-summer consolidati…
What’s Next For Caris Life Sciences (CAI) After 21% Jump?
After soaring by as much as 21.58 percent on Thursday, Caris Life Sciences Inc. (NASDAQ:CAI) heads into the next trading session with investors focused less on a stellar earnings performance and more on whether it can sustain its momentum…
Caris Life Sciences Q2 Earnings Call Highlights
Key Points Interested in Caris Life Sciences, Inc.? Here are five stocks we like better. Caris reported strong second-quarter growth: Revenue rose 45% year over year to $263.7 million, while clinical cases increased 18% to approximately 59…
Biomarker Collaboration and Licensing Deals Report 2016-2026 - Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More
Company Logo Dublin, July 21, 2026 (GLOBE NEWSWIRE) -- The "Biomarker Collaboration and Licensing Deals 2016-2026" has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive and structured analysis of 590+ bi…
Caris Life Sciences (CAI) Stock Looks Undervalued On A 47% Slump
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Caris Life Sciences stock has had a tough run over the past year, y…
Is Caris Life Sciences, Inc. (CAI) Stock Positioned for Growth With AI-Driven Precision Medicine Expansion?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the most promising stocks on our list. TheFly reported on June 1 that Wolfe Research ana…
Is Liquidia Corporation (LQDA) A Good Stock To Buy Now?
Is LQDA a good stock to buy? We came across a bullish thesis on Liquidia Corporation on r/GrowthStockInvesting by symbaeu. In this article, we will summarize the bulls' thesis on LQDA. Liquidia Corporation's share was trading at $76.92 as…
Is Caris Life Sciences, Inc. (CAI) A Good Stock To Buy Now?
Is CAI a good stock to buy? We came across a bullish thesis on Caris Life Sciences, Inc. on InfoArb Sheets's Substack. In this article, we will summarize the bulls' thesis on CAI. Caris Life Sciences, Inc.'s share was trading at $18.47 as…
Caris Life Sciences (CAI) Announces $100M Share Repurchase Program
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best new stocks to buy with the huge upside potential. On June 8, Caris Life Sciences announced that its Board of Directors authorized a program to repurchase up to $100 million of its ou…
Caris Life Sciences Announces Dual Listing on NYSE Texas
IRVING, Texas, June 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced the dual listing of its common stock on NYSE Texa…
European Penny Stocks With Market Caps Over €100M To Consider
European markets have recently shown a lack of direction, with the STOXX Europe 600 Index experiencing a slight decline as investors navigate geopolitical tensions and economic uncertainties. Despite these challenges, penny stocks—often vi…
3 European Dividend Stocks Yielding Up To 7.3%
As European markets navigate a period of uncertainty, marked by fluctuating indices and economic contractions in the eurozone, investors are increasingly looking towards stable income sources such as dividend stocks. In this environment, i…
Caris Life Sciences Authorized Buy Back Up To $100 Mln
(RTTNews) - Caris Life Sciences (CAI), an AI TechBio company, Monday announced that it has been authorized to repurchase up to $100 million of the company's outstanding common stock. The timing, manner, price, and amount of any repurchases…
European Penny Stocks To Consider In May 2026
European markets have recently shown resilience, with the pan-European STOXX Europe 600 Index rising by 3% amid hopes of a de-escalation in the Middle East conflict. As investors navigate these fluctuating conditions, penny stocks—often re…
You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees.
While the rest of Wall Street stayed busy chasing the next artificial intelligence (AI) chip darling, Stanley Druckenmiller was doing what he does best, picking winners before the crowd even catches on. Through his Duquesne Family Office,…
Stanley Druckenmiller Exits State Street Financial Select Sector SPDR ETF, Impacting Portfolio ...
This article first appeared on GuruFocus. Insight into Stanley Druckenmiller (Trades, Portfolio)'s Strategic Moves in Q1 2026 Warning! GuruFocus has detected 3 Warning Signs with NTRA. Is NTRA fairly valued? Test your thesis with our free…
Caris (CAI) Q1 2026 Earnings Call Transcript
Image source: The Motley Fool. Date Thursday, May 7, 2026 at 4:30 p.m. ET Call participants Founder, Chairman, and CEO — David Halbert President — David Spetzler Vice Chairman and Executive Vice President — Brian Brille Chief Commercial Of…
Caris Life Sciences Q1 Earnings Call Highlights
Caris Life Sciences logo Key Points Interested in Caris Life Sciences, Inc.? Here are five stocks we like better. Financial outperformance: Total revenue rose 79% year‑over‑year to $216 million (molecular profiling up 85% to $211M) driven…
Spotlight On European Penny Stocks For May 2026
As the European market navigates through a period of cautious optimism, with central banks maintaining interest rates amid geopolitical uncertainties, investors are keenly observing sectors for potential opportunities. Penny stocks, often…
Is Ecovyst Inc. (ECVT) A Good Stock To Buy Now?
Is ECVT a good stock to buy? We came across a bullish thesis on Ecovyst Inc. on RM Trade Co. ’s Substack. In this article, we will summarize the bulls’ thesis on ECVT. Ecovyst Inc.'s share was trading at $13.83 as of April 21st. ECVT’s tra…
3 Stocks Estimated To Be Trading Up To 43% Below Intrinsic Value
The United States market remained flat over the last week but has experienced a significant 30% increase over the past year, with earnings forecasted to grow by 16% annually. In such an environment, identifying stocks that are trading belo…
Ligand Pharmaceuticals And 2 Other Stocks That May Be Trading At An Estimated Discount
Over the last 7 days, the United States market has remained flat, yet it is up 30% over the past year with earnings expected to grow by 16% per annum in the coming years. In this environment, identifying stocks that may be trading at an es…
Caris Life Sciences, Inc. (CAI) Coverage Begins at Neutral as Piper Cites Need for Growth Acceleration
We recently compiled a list of the Top 10 AI-Powered Biotech Stocks to Buy Right Now. Caris Life Sciences, Inc. is among the best biotech stocks. TheFly reported on April 10 that Piper Sandler began coverage of CAI with a Neutral rating an…
Jefferies Initiates Coverage of Caris Life Sciences Inc. (CAI) With a Buy Rating
Caris Life Sciences Inc. (NASDAQ:CAI) is one of the most oversold healthcare stocks to invest in. Jefferies initiated coverage of Caris Life Sciences Inc. (NASDAQ:CAI) with a Buy rating on April 13, setting a $28 price target on the stock.…
April 2026's Estimated Undervalued Stocks For Savvy Investors
Over the last week, the United States market has seen a 4.4% increase, contributing to an impressive 32% rise over the past year, with earnings expected to grow by 16% annually. In such a thriving environment, identifying stocks that are p…
3 Stocks Estimated To Be Undervalued In April 2026
The United States market has shown robust performance, climbing 1.2% in the last 7 days and up 33% over the past year, with earnings forecasted to grow by 16% annually. In this thriving environment, identifying stocks that are potentially…
European Penny Stocks To Watch In April 2026
As European markets navigate the complexities of geopolitical tensions and fluctuating energy prices, investors are keenly observing how these factors will influence economic growth and market sentiment. In this context, penny stocks—often…
Three Stocks Estimated To Be Priced Below Intrinsic Value In March 2026
Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are potentially priced bel…